Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction
Open Access
- 15 October 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 15 (suppl_2), R220-R226
- https://doi.org/10.1093/hmg/ddl197
Abstract
Noonan syndrome is a relatively common, genetically heterogeneous Mendelian trait with a pleiomorphic phenotype. Prior to the period covered in this review, missense mutations in PTPN11 had been found to account for nearly 50% of Noonan syndrome cases. That gene encodes SHP-2, a protein tyrosine kinase that plays diverse roles in signal transduction including signaling via the RAS-mitogen activated protein kinase (MAPK) pathway. Noonan syndrome-associated PTPN11 mutations are gain-of-function, with most disrupting SHP-2’s activation–inactivation mechanism. Here, we review recent information that has elucidated further the types and effects of PTPN11 defects in Noonan syndrome and compare them to the related, but specific, missense PTPN11 mutations causing other diseases including LEOPARD syndrome and leukemias. These new data derive from biochemical and cell biological studies as well as animal modeling with fruit flies and chick embryos. The discovery of KRAS missense mutation as a minor cause of Noonan syndrome and the pathogenetic mechanisms of those mutants is discussed. Finally, the elucidation of gene defects underlying two phenotypically related disorders, Costello and cardio-facio-cutaneous syndromes is also reviewed. As these genes also encode proteins relevant for RAS-MAPK signal transduction, all of the syndromes discussed in this article now can be understood to constitute a class of disorders caused by dysregulated RAS-MAPK signaling.This publication has 45 references indexed in Scilit:
- Germline Missense Mutations Affecting KRAS Isoform B Are Associated with a Severe Noonan Syndrome PhenotypeAmerican Journal of Human Genetics, 2006
- Germline KRAS mutations cause Noonan syndromeNature Genetics, 2006
- Diversity and Functional Consequences of Germline and Somatic PTPN11 Mutations in Human DiseaseAmerican Journal of Human Genetics, 2006
- Diverse Biochemical Properties of Shp2 MutantsJournal of Biological Chemistry, 2005
- Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cellsBlood, 2005
- Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutationsCancer Cell, 2005
- Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemiaBlood, 2004
- Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemiaNature Genetics, 2003
- Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndromeNature Genetics, 2001
- Hypertelorism With Turner PhenotypeAmerican Journal of Diseases of Children, 1968